Off-market insider buying at Acasti Pharma (V:ACST)

Vimal Kavuru, a Director, acquired 676,371 Common Shares (Actions de cat?gorie A) on an indirect ownership basis for registered holder Shore Pharma LLC at a price of $1.848USD through a private transaction on September 25th, 2023. The insider also acquired 422,732 Warrants Private Offering Sept 2023 with an exercise price of $1.848 through a private transaction on September 25th, 2023. This represents a $1,683,877 investment into the company's shares and an account share holdings change of greater than 100%.

Acasti Pharma is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector and trades on the Nasdaq under the symbol ACST.

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company's clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.